Clinical Trial Update: Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating datopotamab deruxtecan in combination with durvalumab versus datopotamab deruxtecan alone in PD-L1-negative metastatic tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Datopotamab Deruxtecan (Dato-DXd) (datopotamab deruxtecan)
• Durvalumab (Imfinzi) (durvalumab)

Snippet

Sponsor: Queen Mary University of London | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING